Answers are grounded in this paper and cite their sources.
Analysis finds anti-PD-(L)1 agents improve life expectancy in early-stage cancer, suggesting increased productivity.
Investing in anti-PD-(L)1 agents for early-stage disease may not only increase the life expectancy and QALYs for patients in Hungary but also increase productive work years for both patients and caregivers in Hungary. In addition, it may also help to reduce metastatic disease treatments and cancer-related deaths.
No takes yet. Share an insight, caveat, or question.
Ladino et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: